{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:41:00Z","timestamp":1792428060268,"version":"4.5.0"},"reference-count":205,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:00:00Z","timestamp":1792368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:00:00Z","timestamp":1792368000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Urol"],"DOI":"10.1038\/s41585-026-01194-z","type":"journal-article","created":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:02:06Z","timestamp":1792425726000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Rare prostate cancer histologies: detection, characteristics and treatment"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8754-5198","authenticated-orcid":false,"given":"B\u00e1rbara Vieira Lima Aguiar","family":"Mel\u00e3o","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4663-1521","authenticated-orcid":false,"given":"Denis Leonardo","family":"Jardim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1274-7200","authenticated-orcid":false,"given":"Roger","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrina","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1076-0428","authenticated-orcid":false,"given":"Neeraj","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3965-3394","authenticated-orcid":false,"given":"Petros","family":"Grivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Briganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Necchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6049-5293","authenticated-orcid":false,"given":"Liang","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5723-1972","authenticated-orcid":false,"given":"Philippe E.","family":"Spiess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,19]]},"reference":[{"key":"1194_CR1","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1097\/JU.0000000000001011","volume":"204","author":"C Bronkema","year":"2020","unstructured":"Bronkema, C. et al. Rare histological variants of prostate adenocarcinoma: a National Cancer Database Analysis. J. Urol. 204, 260\u2013266 https:\/\/doi.org\/10.1097\/JU.0000000000001011 (2020).","journal-title":"J. Urol."},{"key":"1194_CR2","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.eururo.2022.02.006","volume":"82","author":"J Zhou","year":"2022","unstructured":"Zhou, J., Ding, J. & Qi, J. Comparison of typical prostate adenocarcinoma and rare histological variant prostate cancer showed different characteristics and prognosis: a surveillance, epidemiology, and end results database analysis. Eur. Urol. 82, 152\u2013155 https:\/\/doi.org\/10.1016\/j.eururo.2022.02.006 (2022).","journal-title":"Eur. Urol."},{"key":"1194_CR3","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1111\/his.14711","volume":"81","author":"JG Kench","year":"2022","unstructured":"Kench, J. G. et al. WHO Classification of Tumours fifth edition: evolving issues in the classification, diagnosis, and prognostication of prostate cancer. Histopathology 81, 447\u2013458 https:\/\/doi.org\/10.1111\/his.14711 (2022).","journal-title":"Histopathology"},{"key":"1194_CR4","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3322\/caac.21388","volume":"67","author":"MB Amin","year":"2017","unstructured":"Amin, M. B. et al. The Eighth Edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging. CA Cancer J. Clin. 67, 93\u201399 https:\/\/doi.org\/10.3322\/caac.21388 (2017).","journal-title":"CA Cancer J. Clin."},{"key":"1194_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15030796","volume":"15","author":"S Jetty","year":"2023","unstructured":"Jetty, S. et al. Prostate cancer \u2014 PET imaging update. Cancers 15, 796 https:\/\/doi.org\/10.3390\/cancers15030796 (2023).","journal-title":"Cancers"},{"key":"1194_CR6","unstructured":"Spratt, D. E., Srinivas, S., Adra, N. et al. NCCN Guidelines Version 7.2026 Prostate Cancer, https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf (2026)."},{"key":"1194_CR7","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.humpath.2022.08.006","volume":"136","author":"SK Mohanty","year":"2023","unstructured":"Mohanty, S. K., Lobo, A. & Cheng, L. The 2022 revision of the World Health Organization classification of tumors of the urinary system and male genital organs: advances and challenges. Hum. Pathol. 136, 123\u2013143 https:\/\/doi.org\/10.1016\/j.humpath.2022.08.006 (2023).","journal-title":"Hum. Pathol."},{"key":"1194_CR8","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1097\/00000478-198504000-00006","volume":"9","author":"JI Epstein","year":"1985","unstructured":"Epstein, J. I. & Lieberman, P. H. Mucinous adenocarcinoma of the prostate gland. Am. J. Surg. Pathol. 9, 299\u2013308 https:\/\/doi.org\/10.1097\/00000478-198504000-00006 (1985).","journal-title":"Am. J. Surg. Pathol."},{"key":"1194_CR9","doi-asserted-by":"publisher","first-page":"952","DOI":"10.5858\/arpa.2022-0509-RA","volume":"148","author":"N Riddle","year":"2024","unstructured":"Riddle, N. et al. Recent advances in genitourinary tumors: updates from the 5th edition of the World Health Organization Blue Book Series. Arch. Pathol. Lab. Med. 148, 952\u2013964 https:\/\/doi.org\/10.5858\/arpa.2022-0509-RA (2024).","journal-title":"Arch. Pathol. Lab. Med."},{"key":"1194_CR10","doi-asserted-by":"publisher","unstructured":"Siech, C. et al. Rare histological prostate cancer subtypes: cancer-specific and other-cause mortality. Prostate Cancer Prostatic Dis. https:\/\/doi.org\/10.1038\/s41391-024-00866-4 (2024).","DOI":"10.1038\/s41391-024-00866-4"},{"key":"1194_CR11","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/s41586-022-05154-6","volume":"609","author":"W Jaratlerdsiri","year":"2022","unstructured":"Jaratlerdsiri, W. et al. African-specific molecular taxonomy of prostate cancer. Nature 609, 552\u2013559 https:\/\/doi.org\/10.1038\/s41586-022-05154-6 (2022).","journal-title":"Nature"},{"key":"1194_CR12","doi-asserted-by":"publisher","first-page":"4492","DOI":"10.1172\/JCI128212","volume":"129","author":"MP Labrecque","year":"2019","unstructured":"Labrecque, M. P. et al. Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer. J. Clin. Invest. 129, 4492\u20134505 https:\/\/doi.org\/10.1172\/JCI128212 (2019).","journal-title":"J. Clin. Invest."},{"key":"1194_CR13","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.3390\/curroncol29030152","volume":"29","author":"S Cozzi","year":"2022","unstructured":"Cozzi, S. et al. Adenoid cystic carcinoma\/basal cell carcinoma of the prostate: overview and update on rare prostate cancer subtypes. Curr. Oncol. 29, 1866\u20131876 https:\/\/doi.org\/10.3390\/curroncol29030152 (2022).","journal-title":"Curr. Oncol."},{"key":"1194_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12123792","volume":"12","author":"N Spetsieris","year":"2020","unstructured":"Spetsieris, N., Boukovala, M., Patsakis, G., Alafis, I. & Efstathiou, E. Neuroendocrine and aggressive-variant prostate cancer. Cancers 12, 3792 https:\/\/doi.org\/10.3390\/cancers12123792 (2020).","journal-title":"Cancers"},{"key":"1194_CR15","doi-asserted-by":"publisher","first-page":"550","DOI":"10.5858\/arpa.2018-0334-RA","volume":"143","author":"GP Paner","year":"2019","unstructured":"Paner, G. P., Gandhi, J., Choy, B. & Amin, M. B. Essential updates in grading, morphotyping, reporting, and staging of prostate carcinoma for general surgical pathologists. Arch. Pathol. Lab. Med. 143, 550\u2013564 https:\/\/doi.org\/10.5858\/arpa.2018-0334-RA (2019).","journal-title":"Arch. Pathol. Lab. Med."},{"key":"1194_CR16","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1148\/radiol.11091409","volume":"259","author":"T Hambrock","year":"2011","unstructured":"Hambrock, T. et al. Relationship between apparent diffusion coefficients at 3.0-T MR imaging and Gleason grade in peripheral zone prostate cancer. Radiology 259, 453\u2013461 https:\/\/doi.org\/10.1148\/radiol.11091409 (2011).","journal-title":"Radiology"},{"key":"1194_CR17","doi-asserted-by":"publisher","first-page":"756","DOI":"10.2214\/AJR.15.14912","volume":"206","author":"AM H\u00f6tker","year":"2016","unstructured":"H\u00f6tker, A. M. et al. Assessment of prostate cancer aggressiveness by use of the combination of quantitative DWI and dynamic contrast-enhanced MRI. AJR Am. J. Roentgenol. 206, 756\u2013763 https:\/\/doi.org\/10.2214\/AJR.15.14912 (2016).","journal-title":"AJR Am. J. Roentgenol."},{"key":"1194_CR18","doi-asserted-by":"publisher","first-page":"e87","DOI":"10.1097\/PAS.0000000000001497","volume":"44","author":"GJLH van Leenders","year":"2020","unstructured":"van Leenders, G. J. L. H. et al. The 2019 International Society of Urological Pathology (ISUP) Consensus Conference on Grading of Prostatic Carcinoma. Am. J. Surg. Pathol. 44, e87\u2013e99 https:\/\/doi.org\/10.1097\/PAS.0000000000001497 (2020).","journal-title":"Am. J. Surg. Pathol."},{"key":"1194_CR19","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.eururo.2022.07.002","volume":"82","author":"GJ Netto","year":"2022","unstructured":"Netto, G. J. et al. The 2022 World Health Organization Classification of Tumors of the Urinary System and Male Genital Organs-Part B: Prostate and Urinary Tract Tumors. Eur. Urol. 82, 469\u2013482 https:\/\/doi.org\/10.1016\/j.eururo.2022.07.002 (2022).","journal-title":"Eur. Urol."},{"key":"1194_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00377","volume":"8","author":"A Carneiro","year":"2018","unstructured":"Carneiro, A. et al. The role of immunohistochemical analysis as a tool for the diagnosis, prognostic evaluation and treatment of prostate cancer: a systematic review of the literature. Front. Oncol. 8, 377 https:\/\/doi.org\/10.3389\/fonc.2018.00377 (2018).","journal-title":"Front. Oncol."},{"key":"1194_CR21","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1097\/PAP.0000000000000200","volume":"25","author":"SW Fine","year":"2018","unstructured":"Fine, S. W. Evolution in prostate cancer staging: pathology updates from AJCC 8th edition and opportunities that remain. Adv. Anat. Pathol. 25, 327\u2013332 https:\/\/doi.org\/10.1097\/PAP.0000000000000200 (2018).","journal-title":"Adv. Anat. Pathol."},{"key":"1194_CR22","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK-25-473636","volume":"45","author":"W Abida","year":"2025","unstructured":"Abida, W., Beltran, H. & Raychaudhuri, R. State of the art: personalizing treatment for patients with metastatic castration-resistant prostate cancer. Am. Soc. Clin. Oncol. Educ. Book\u00a045, e473636 https:\/\/doi.org\/10.1200\/EDBK-25-473636 (2025).","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"1194_CR23","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1158\/1535-7163.MCT-19-0531","volume":"19","author":"NA Dawson","year":"2020","unstructured":"Dawson, N. A. et al. An emerging landscape for canonical and actionable molecular alterations in primary and metastatic prostate cancer. Mol. Cancer Ther. 19, 1373\u20131382 https:\/\/doi.org\/10.1158\/1535-7163.MCT-19-0531 (2020).","journal-title":"Mol. Cancer Ther."},{"key":"1194_CR24","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1200\/JCO-24-02608","volume":"43","author":"EY Yu","year":"2025","unstructured":"Yu, E. Y. et al. Germline and somatic genomic testing for metastatic prostate cancer: ASCO guideline. J. Clin. Oncol. 43, 748\u2013758 https:\/\/doi.org\/10.1200\/JCO-24-02608 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1194_CR25","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nm.4045","volume":"22","author":"H Beltran","year":"2016","unstructured":"Beltran, H. et al. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat. Med. 22, 298\u2013305 https:\/\/doi.org\/10.1038\/nm.4045 (2016).","journal-title":"Nat. Med."},{"key":"1194_CR26","unstructured":"NCCN. NCCN Clinical Practice Guidelines on Prostate Cancer https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf version 1 (2025)."},{"key":"1194_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3976-z","volume":"18","author":"R B\u00f6ttcher","year":"2018","unstructured":"B\u00f6ttcher, R. et al. Cribriform and intraductal prostate cancer are associated with increased genomic instability and distinct genomic alterations. BMC Cancer 18, 8 https:\/\/doi.org\/10.1186\/s12885-017-3976-z (2018).","journal-title":"BMC Cancer"},{"key":"1194_CR28","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.eururo.2014.08.007","volume":"67","author":"GP Risbridger","year":"2015","unstructured":"Risbridger, G. P. et al. Patient-derived xenografts reveal that intraductal carcinoma of the prostate is a prominent pathology in BRCA2 mutation carriers with prostate cancer and correlates with poor prognosis. Eur. Urol. 67, 496\u2013503 https:\/\/doi.org\/10.1016\/j.eururo.2014.08.007 (2015).","journal-title":"Eur. Urol."},{"key":"1194_CR29","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1093\/oxfordjournals.molbev.a025859","volume":"15","author":"GL Galloway","year":"1998","unstructured":"Galloway, G. L., Malmberg, R. L. & Price, R. A. Phylogenetic utility of the nuclear gene arginine decarboxylase: an example from Brassicaceae. Mol. Biol. Evol. 15, 1312\u20131320 https:\/\/doi.org\/10.1093\/oxfordjournals.molbev.a025859 (1998).","journal-title":"Mol. Biol. Evol."},{"key":"1194_CR30","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1056\/NEJMoa1603144","volume":"375","author":"CC Pritchard","year":"2016","unstructured":"Pritchard, C. C. et al. Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N. Engl. J. Med. 375, 443\u2013453 https:\/\/doi.org\/10.1056\/NEJMoa1603144 (2016).","journal-title":"N. Engl. J. Med."},{"key":"1194_CR31","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1038\/modpathol.2011.7","volume":"24","author":"TL Lotan","year":"2011","unstructured":"Lotan, T. L. et al. ERG gene rearrangements are common in prostatic small cell carcinomas. Mod. Pathol. 24, 820\u2013828 https:\/\/doi.org\/10.1038\/modpathol.2011.7 (2011).","journal-title":"Mod. Pathol."},{"key":"1194_CR32","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1111\/his.14205","volume":"77","author":"M Alhamar","year":"2020","unstructured":"Alhamar, M. et al. Gene fusion characterisation of rare aggressive prostate cancer variants-adenosquamous carcinoma, pleomorphic giant-cell carcinoma, and sarcomatoid carcinoma: an analysis of 19 cases. Histopathology 77, 890\u2013899 https:\/\/doi.org\/10.1111\/his.14205 (2020).","journal-title":"Histopathology"},{"key":"1194_CR33","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1200\/JCO.2017.77.6880","volume":"36","author":"R Aggarwal","year":"2018","unstructured":"Aggarwal, R. et al. Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study. J. Clin. Oncol. 36, 2492\u20132503 https:\/\/doi.org\/10.1200\/JCO.2017.77.6880 (2018).","journal-title":"J. Clin. Oncol."},{"key":"1194_CR34","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1158\/1078-0432.CCR-15-1259","volume":"22","author":"AM Aparicio","year":"2016","unstructured":"Aparicio, A. M. et al. Combined tumor suppressor defects characterize clinically defined aggressive variant prostate cancers. Clin. Cancer Res. 22, 1520\u20131530 https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-1259 (2016).","journal-title":"Clin. Cancer Res."},{"key":"1194_CR35","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1002\/ijc.34949","volume":"155","author":"S Weiss","year":"2024","unstructured":"Weiss, S. et al. Exploring the tumor genomic landscape of aggressive prostate cancer by whole-genome sequencing of tissue or liquid biopsies. Int. J. Cancer 155, 298\u2013313 https:\/\/doi.org\/10.1002\/ijc.34949 (2024).","journal-title":"Int. J. Cancer"},{"key":"1194_CR36","doi-asserted-by":"publisher","first-page":"82504","DOI":"10.18632\/oncotarget.12697","volume":"7","author":"MT Schweizer","year":"2016","unstructured":"Schweizer, M. T. et al. Mismatch repair deficiency may be common in ductal adenocarcinoma of the prostate. Oncotarget 7, 82504\u201382510 https:\/\/doi.org\/10.18632\/oncotarget.12697 (2016).","journal-title":"Oncotarget"},{"key":"1194_CR37","doi-asserted-by":"publisher","DOI":"10.1002\/2056-4538.70026","volume":"11","author":"Q Zhu","year":"2025","unstructured":"Zhu, Q. et al. Genomic features of liquid biopsies from patients with prostate cancer with and without ductal adenocarcinoma. J. Pathol. Clin. Res. 11, e70026 https:\/\/doi.org\/10.1002\/2056-4538.70026 (2025).","journal-title":"J. Pathol. Clin. Res."},{"key":"1194_CR38","doi-asserted-by":"publisher","DOI":"10.1200\/PO.18.00327","author":"MT Schweizer","year":"2019","unstructured":"Schweizer, M. T. et al. Genomic characterization of prostatic ductal adenocarcinoma identifies a high prevalence of DNA repair gene mutations. JCO Precis. Oncol. https:\/\/doi.org\/10.1200\/PO.18.00327 (2019).","journal-title":"JCO Precis. Oncol."},{"key":"1194_CR39","doi-asserted-by":"publisher","first-page":"14723","DOI":"10.18632\/oncotarget.24515","volume":"9","author":"K Inamura","year":"2018","unstructured":"Inamura, K. Prostatic cancers: understanding their molecular pathology and the 2016 WHO classification. Oncotarget 9, 14723\u201314737 https:\/\/doi.org\/10.18632\/oncotarget.24515 (2018).","journal-title":"Oncotarget"},{"key":"1194_CR40","doi-asserted-by":"publisher","DOI":"10.1200\/PO.22.00104","volume":"7","author":"HH Cheng","year":"2023","unstructured":"Cheng, H. H. et al. Internet-based germline genetic testing for men with metastatic prostate cancer. JCO Precis. Oncol. 7, e2200104 https:\/\/doi.org\/10.1200\/PO.22.00104 (2023).","journal-title":"JCO Precis. Oncol."},{"key":"1194_CR41","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S1470-2045(19)30739-9","volume":"21","author":"W Bulten","year":"2020","unstructured":"Bulten, W. et al. Automated deep-learning system for Gleason grading of prostate cancer using biopsies: a diagnostic study. Lancet Oncol. 21, 233\u2013241 https:\/\/doi.org\/10.1016\/S1470-2045(19)30739-9 (2020).","journal-title":"Lancet Oncol."},{"key":"1194_CR42","doi-asserted-by":"publisher","DOI":"10.3390\/cancers18050780","volume":"18","author":"K Sklinda","year":"2026","unstructured":"Sklinda, K. et al. Radiomics-based characterization of aggressive prostate cancer variants: diagnostic challenges and opportunities. Cancers 18, 780 https:\/\/doi.org\/10.3390\/cancers18050780 (2026).","journal-title":"Cancers"},{"key":"1194_CR43","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41585-025-01070-2","volume":"23","author":"HM Ni","year":"2026","unstructured":"Ni, H. M. et al. The state of the art in artificial intelligence and digital pathology in prostate cancer. Nat. Rev. Urol. 23, 13\u201328 https:\/\/doi.org\/10.1038\/s41585-025-01070-2 (2026).","journal-title":"Nat. Rev. Urol."},{"key":"1194_CR44","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1158\/1078-0432.CCR-25-3327","volume":"32","author":"S Medina","year":"2026","unstructured":"Medina, S. et al. A computational pathology model to predict docetaxel benefit in localized high-risk and metastatic prostate cancer. Clin. Cancer Res. 32, 645\u2013653 https:\/\/doi.org\/10.1158\/1078-0432.CCR-25-3327 (2026).","journal-title":"Clin. Cancer Res."},{"key":"1194_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-020-02045-9","volume":"21","author":"N Ramesh","year":"2020","unstructured":"Ramesh, N. et al. Decoding the evolutionary response to prostate cancer therapy by plasma genome sequencing. Genome Biol. 21, 162 https:\/\/doi.org\/10.1186\/s13059-020-02045-9 (2020).","journal-title":"Genome Biol."},{"key":"1194_CR46","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/j.eururo.2016.08.012","volume":"71","author":"M Del Re","year":"2017","unstructured":"Del Re, M. et al. The detection of androgen receptor splice variant 7 in plasma-derived exosomal RNA strongly predicts resistance to hormonal therapy in metastatic prostate cancer patients. Eur. Urol. 71, 680\u2013687 https:\/\/doi.org\/10.1016\/j.eururo.2016.08.012 (2017).","journal-title":"Eur. Urol."},{"key":"1194_CR47","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1001\/jamaoncol.2016.0097","volume":"2","author":"J McKiernan","year":"2016","unstructured":"McKiernan, J. et al. A novel urine exosome gene expression assay to predict high-grade prostate cancer at initial biopsy. JAMA Oncol. 2, 882\u2013889 https:\/\/doi.org\/10.1001\/jamaoncol.2016.0097 (2016).","journal-title":"JAMA Oncol."},{"key":"1194_CR48","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1053\/hp.2000.6698","volume":"31","author":"L Bubendorf","year":"2000","unstructured":"Bubendorf, L. et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum. Pathol. 31, 578\u2013583 https:\/\/doi.org\/10.1053\/hp.2000.6698 (2000).","journal-title":"Hum. Pathol."},{"key":"1194_CR49","doi-asserted-by":"publisher","first-page":"E334","DOI":"10.5489\/cuaj.8769","volume":"18","author":"A Ullah","year":"2024","unstructured":"Ullah, A. et al. Clinicopathologic and survival patterns among prostate carcinosarcoma patients in the U.S. An analysis of SEER database. Can. Urol. Assoc. J. 18, E334\u2013E338 https:\/\/doi.org\/10.5489\/cuaj.8769 (2024).","journal-title":"Can. Urol. Assoc. J."},{"key":"1194_CR50","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/bco2.60","volume":"2","author":"N Ranasinha","year":"2021","unstructured":"Ranasinha, N. et al. Ductal adenocarcinoma of the prostate: a systematic review and meta-analysis of incidence, presentation, prognosis, and management. BJUI Compass 2, 13\u201323 https:\/\/doi.org\/10.1002\/bco2.60 (2021).","journal-title":"BJUI Compass"},{"key":"1194_CR51","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/S0140-6736(25)02221-4","volume":"407","author":"V Fonteyne","year":"2026","unstructured":"Fonteyne, V., Tree, A., Castro, E., Touijer, K. & Walz, J. Prostate cancer. Lancet 407, 622\u2013636 https:\/\/doi.org\/10.1016\/S0140-6736(25)02221-4 (2026).","journal-title":"Lancet"},{"key":"1194_CR52","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.1158\/0008-5472.CAN-23-0593","volume":"83","author":"A Lundberg","year":"2023","unstructured":"Lundberg, A. et al. The genomic and epigenomic landscape of double-negative metastatic prostate cancer. Cancer Res. 83, 2763\u20132774 https:\/\/doi.org\/10.1158\/0008-5472.CAN-23-0593 (2023).","journal-title":"Cancer Res."},{"key":"1194_CR53","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1158\/1078-0432.CCR-24-2061","volume":"31","author":"MC Haffner","year":"2025","unstructured":"Haffner, M. C. et al. Framework for the pathology workup of metastatic castration-resistant prostate cancer biopsies. Clin. Cancer Res. 31, 466\u2013478 https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-2061 (2025).","journal-title":"Clin. Cancer Res."},{"key":"1194_CR54","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.humpath.2022.07.018","volume":"128","author":"T Zhao","year":"2022","unstructured":"Zhao, T. et al. Mucinous adenocarcinoma of the prostatic urethra after brachytherapy for prostatic adenocarcinoma: a case series. Hum. Pathol. 128, 101\u2013109 https:\/\/doi.org\/10.1016\/j.humpath.2022.07.018 (2022).","journal-title":"Hum. Pathol."},{"key":"1194_CR55","doi-asserted-by":"publisher","first-page":"596","DOI":"10.4103\/jcrt.JCRT_673_18","volume":"17","author":"N Karsiyakali","year":"2021","unstructured":"Karsiyakali, N. et al. The prostatic adenocarcinoma with mucinous features: a review of the literature with three case reports. J. Cancer Res. Ther. 17, 596\u2013598 https:\/\/doi.org\/10.4103\/jcrt.JCRT_673_18 (2021).","journal-title":"J. Cancer Res. Ther."},{"key":"1194_CR56","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1111\/his.13278","volume":"71","author":"H Samaratunga","year":"2017","unstructured":"Samaratunga, H. et al. Mucinous adenocarcinoma of prostate and prostatic adenocarcinoma with mucinous components: a clinicopathological analysis of 143 cases. Histopathology 71, 641\u2013647 https:\/\/doi.org\/10.1111\/his.13278 (2017).","journal-title":"Histopathology"},{"key":"1194_CR57","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.3389\/fonc.2019.01467","volume":"9","author":"F Zhao","year":"2019","unstructured":"Zhao, F. et al. Mucinous prostate cancer shows similar prognosis to typical prostate acinar carcinoma: a large population-based and propensity score-matched study. Front. Oncol. 9, 1467 https:\/\/doi.org\/10.3389\/fonc.2019.01467 (2019).","journal-title":"Front. Oncol."},{"key":"1194_CR58","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14051297","volume":"14","author":"JW Bong","year":"2022","unstructured":"Bong, J. W. et al. Prognosis and sensitivity of adjuvant chemotherapy in mucinous colorectal adenocarcinoma without distant metastasis. Cancers 14, 1297 https:\/\/doi.org\/10.3390\/cancers14051297 (2022).","journal-title":"Cancers"},{"key":"1194_CR59","doi-asserted-by":"publisher","first-page":"S80","DOI":"10.1038\/modpathol.2017.132","volume":"31","author":"AO Osunkoya","year":"2018","unstructured":"Osunkoya, A. O. Mucinous and secondary tumors of the prostate. Mod. Pathol. 31, S80\u2013S95 https:\/\/doi.org\/10.1038\/modpathol.2017.132 (2018).","journal-title":"Mod. Pathol."},{"key":"1194_CR60","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1007\/s00261-019-01956-x","volume":"44","author":"K Yamada","year":"2019","unstructured":"Yamada, K., Kozawa, N., Nagano, H. & Fujita, M. MRI features of mucinous adenocarcinoma of the prostate: report of four cases. Abdom. Radiol. 44, 1261\u20131268 https:\/\/doi.org\/10.1007\/s00261-019-01956-x (2019).","journal-title":"Abdom. Radiol."},{"key":"1194_CR61","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1097\/RLU.0000000000006004","volume":"50","author":"Z Sun","year":"2025","unstructured":"Sun, Z., Jiang, X., Fu, G., Sun, S. & Tao, W. The characteristics of prostate mucinous adenocarcinoma visualized by 68 Ga-PSMA, 68 Ga-FAPI, and 18 F-FDG PET\/CT. Clin. Nucl. Med. 50, 743\u2013745 https:\/\/doi.org\/10.1097\/RLU.0000000000006004 (2025).","journal-title":"Clin. Nucl. Med."},{"key":"1194_CR62","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1097\/PAS.0b013e3181589f72","volume":"32","author":"AO Osunkoya","year":"2008","unstructured":"Osunkoya, A. O., Nielsen, M. E. & Epstein, J. I. Prognosis of mucinous adenocarcinoma of the prostate treated by radical prostatectomy: a study of 47 cases. Am. J. Surg. Pathol. 32, 468\u2013472 https:\/\/doi.org\/10.1097\/PAS.0b013e3181589f72 (2008).","journal-title":"Am. J. Surg. Pathol."},{"key":"1194_CR63","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1097\/PAS.0000000000000530","volume":"40","author":"JI Epstein","year":"2016","unstructured":"Epstein, J. I. et al. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: definition of grading patterns and proposal for a new grading system. Am. J. Surg. Pathol. 40, 244\u2013252 https:\/\/doi.org\/10.1097\/PAS.0000000000000530 (2016).","journal-title":"Am. J. Surg. Pathol."},{"key":"1194_CR64","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.504381","volume":"10","author":"Y Zhang","year":"2020","unstructured":"Zhang, Y. et al. Case report: prostate adenocarcinoma with mucinous features of normal-level serum PSA, atypical imaging, biopsy-negative, and peculiar urethrocystoscopic manifestation. Front. Oncol. 10, 504381 https:\/\/doi.org\/10.3389\/fonc.2020.504381 (2020).","journal-title":"Front. Oncol."},{"key":"1194_CR65","doi-asserted-by":"publisher","DOI":"10.15557\/jou.2025.0027","volume":"25","author":"M Montatore","year":"2025","unstructured":"Montatore, M., Eusebi, L., Masino, F., Balbino, M. & Guglielmi, G. Mucinous adenocarcinoma of the prostate: a rare tumor - case report and literature review. J. Ultrason. 25, 20250027 https:\/\/doi.org\/10.15557\/jou.2025.0027 (2025).","journal-title":"J. Ultrason."},{"key":"1194_CR66","doi-asserted-by":"publisher","first-page":"5865","DOI":"10.1245\/s10434-026-19245-5","volume":"33","author":"C Siech","year":"2026","unstructured":"Siech, C. et al. Cancer-specific mortality in rare histological subtypes of prostate cancer: radical prostatectomy versus radiation therapy. Ann. Surg. Oncol. 33, 5865\u20135873 https:\/\/doi.org\/10.1245\/s10434-026-19245-5 (2026).","journal-title":"Ann. Surg. Oncol."},{"key":"1194_CR67","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/s0022-5347(17)35054-1","volume":"151","author":"JM Teichman","year":"1994","unstructured":"Teichman, J. M., Shabaik, A. & Demby, A. M. Mucinous adenocarcinoma of the prostate and hormone sensitivity. J. Urol. 151, 701\u2013702 https:\/\/doi.org\/10.1016\/s0022-5347(17)35054-1 (1994).","journal-title":"J. Urol."},{"key":"1194_CR68","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.4065\/mcp.2010.0463","volume":"85","author":"JN Warner","year":"2010","unstructured":"Warner, J. N., Nakamura, L. Y., Pacelli, A., Humphreys, M. R. & Castle, E. P. Primary signet ring cell carcinoma of the prostate. Mayo Clin. Proc. 85, 1130\u20131136 https:\/\/doi.org\/10.4065\/mcp.2010.0463 (2010).","journal-title":"Mayo Clin. Proc."},{"key":"1194_CR69","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.urology.2006.04.028","volume":"68","author":"BR Lane","year":"2006","unstructured":"Lane, B. R. et al. Mucinous adenocarcinoma of the prostate does not confer poor prognosis. Urology 68, 825\u2013830 https:\/\/doi.org\/10.1016\/j.urology.2006.04.028 (2006).","journal-title":"Urology"},{"key":"1194_CR70","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a030411","author":"PA Humphrey","year":"2017","unstructured":"Humphrey, P. A. Histopathology of prostate cancer. Cold Spring Harb. Perspect. Med.\u00a07, a030411\u00a0https:\/\/doi.org\/10.1101\/cshperspect.a030411 (2017).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"1194_CR71","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/j.euf.2020.10.007","volume":"7","author":"Y Zong","year":"2021","unstructured":"Zong, Y. et al. Intraductal carcinoma of the prostate: pathogenesis and molecular perspectives. Eur. Urol. Focus. 7, 955\u2013963 https:\/\/doi.org\/10.1016\/j.euf.2020.10.007 (2021).","journal-title":"Eur. Urol. Focus."},{"key":"1194_CR72","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1097\/PAP.0000000000000547","volume":"33","author":"RB Shah","year":"2026","unstructured":"Shah, R. B., Varma, M., Zhou, M., Paner, G. P. & Kristiansen, G. Diagnosis and reporting of intraductal carcinoma of the prostate: a guide for practising pathologists with excerpts from the Genitourinary Pathology Society and the International Society of Urological Pathology Joint Expert Consultation. Adv. Anat. Pathol. 33, 331\u2013341 https:\/\/doi.org\/10.1097\/PAP.0000000000000547 (2026).","journal-title":"Adv. Anat. Pathol."},{"key":"1194_CR73","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.eururo.2017.03.013","volume":"72","author":"LH Porter","year":"2017","unstructured":"Porter, L. H. et al. Systematic review links the prevalence of intraductal carcinoma of the prostate to prostate cancer risk categories. Eur. Urol. 72, 492\u2013495 https:\/\/doi.org\/10.1016\/j.eururo.2017.03.013 (2017).","journal-title":"Eur. Urol."},{"key":"1194_CR74","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222313125","volume":"22","author":"M Kang","year":"2021","unstructured":"Kang, M., Lee, H., Byeon, S. J., Kwon, G. Y. & Jeon, S. S. Genomic features and clinical implications of intraductal carcinoma of the prostate. Int. J. Mol. Sci. 22, 13125 https:\/\/doi.org\/10.3390\/ijms222313125 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"1194_CR75","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.3349\/ymj.2016.57.5.1054","volume":"57","author":"MK Divatia","year":"2016","unstructured":"Divatia, M. K. & Ro, J. Y. Intraductal carcinoma of the prostate gland: recent advances. Yonsei Med. J. 57, 1054\u20131062 https:\/\/doi.org\/10.3349\/ymj.2016.57.5.1054 (2016).","journal-title":"Yonsei Med. J."},{"key":"1194_CR76","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.14670\/HH-18-939","volume":"40","author":"IM Grypari","year":"2025","unstructured":"Grypari, I. M., Pomoni, A. & Tzelepi, V. Intraductal carcinoma of the prostate: a comprehensive literature review focused on grading challenges and controversies. Histol. Histopathol. 40, 1869\u20131888 https:\/\/doi.org\/10.14670\/HH-18-939 (2025).","journal-title":"Histol. Histopathol."},{"key":"1194_CR77","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13246243","volume":"13","author":"MK Diop","year":"2021","unstructured":"Diop, M. K. et al. Identification of morphologic criteria associated with biochemical recurrence in intraductal carcinoma of the prostate. Cancers 13, 6243 https:\/\/doi.org\/10.3390\/cancers13246243 (2021).","journal-title":"Cancers"},{"key":"1194_CR78","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1097\/MOU.0000000000001038","volume":"32","author":"G Wasinger","year":"2022","unstructured":"Wasinger, G., Oszwald, A., Shariat, S. F. & Comp\u00e9rat, E. Histological patterns, subtypes and aspects of prostate cancer: different aspects, different outcomes. Curr. Opin. Urol. 32, 643\u2013648 https:\/\/doi.org\/10.1097\/MOU.0000000000001038 (2022).","journal-title":"Curr. Opin. Urol."},{"key":"1194_CR79","doi-asserted-by":"publisher","DOI":"10.1186\/s12894-025-01690-1","volume":"25","author":"F Cao","year":"2025","unstructured":"Cao, F. et al. Prognostic value of intraductal carcinoma subtypes and postoperative radiotherapy for localized prostate cancer. BMC Urol. 25, 10 https:\/\/doi.org\/10.1186\/s12894-025-01690-1 (2025).","journal-title":"BMC Urol."},{"key":"1194_CR80","doi-asserted-by":"publisher","DOI":"10.1186\/s13244-021-01024-3","volume":"12","author":"C Han","year":"2021","unstructured":"Han, C. et al. Differential diagnosis of uncommon prostate diseases: combining mpMRI and clinical information. Insights Imaging 12, 79 https:\/\/doi.org\/10.1186\/s13244-021-01024-3 (2021).","journal-title":"Insights Imaging"},{"key":"1194_CR81","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1016\/j.humpath.2014.03.011","volume":"45","author":"K Miyai","year":"2014","unstructured":"Miyai, K. et al. Clinicopathological analysis of intraductal proliferative lesions of prostate: intraductal carcinoma of prostate, high-grade prostatic intraepithelial neoplasia, and atypical cribriform lesion. Hum. Pathol. 45, 1572\u20131581 https:\/\/doi.org\/10.1016\/j.humpath.2014.03.011 (2014).","journal-title":"Hum. Pathol."},{"key":"1194_CR82","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/s41585-021-00447-3","volume":"18","author":"W Ranasinghe","year":"2021","unstructured":"Ranasinghe, W. et al. Optimizing the diagnosis and management of ductal prostate cancer. Nat. Rev. Urol. 18, 337\u2013358 https:\/\/doi.org\/10.1038\/s41585-021-00447-3 (2021).","journal-title":"Nat. Rev. Urol."},{"key":"1194_CR83","doi-asserted-by":"publisher","first-page":"e67","DOI":"10.1097\/PAS.0000000000000609","volume":"40","author":"SE Wobker","year":"2016","unstructured":"Wobker, S. E. & Epstein, J. I. Differential diagnosis of intraductal lesions of the prostate. Am. J. Surg. Pathol. 40, e67\u2013e82 https:\/\/doi.org\/10.1097\/PAS.0000000000000609 (2016).","journal-title":"Am. J. Surg. Pathol."},{"key":"1194_CR84","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6939","volume":"13","author":"S Zhu","year":"2024","unstructured":"Zhu, S., Xu, N. & Zeng, H. Molecular complexity of intraductal carcinoma of the prostate. Cancer Med. 13, e6939 https:\/\/doi.org\/10.1002\/cam4.6939 (2024).","journal-title":"Cancer Med."},{"key":"1194_CR85","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15235512","volume":"15","author":"M Bernhardt","year":"2023","unstructured":"Bernhardt, M. & Kristiansen, G. Molecular alterations in intraductal carcinoma of the prostate. Cancers 15, 5512 https:\/\/doi.org\/10.3390\/cancers15235512 (2023).","journal-title":"Cancers"},{"key":"1194_CR86","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-023-05582-5","volume":"150","author":"Y Cui","year":"2024","unstructured":"Cui, Y. et al. Nomogram for predicting the overall survival and cancer-specific survival of patients with intraductal carcinoma of the prostate. J. Cancer Res. Clin. Oncol. 150, 45 https:\/\/doi.org\/10.1007\/s00432-023-05582-5 (2024).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"1194_CR87","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/s41585-019-0164-8","volume":"16","author":"RA Taylor","year":"2019","unstructured":"Taylor, R. A. et al. The influence of BRCA2 mutation on localized prostate cancer. Nat. Rev. Urol. 16, 281\u2013290 https:\/\/doi.org\/10.1038\/s41585-019-0164-8 (2019).","journal-title":"Nat. Rev. Urol."},{"key":"1194_CR88","doi-asserted-by":"publisher","first-page":"55374","DOI":"10.18632\/oncotarget.19520","volume":"8","author":"J Zhao","year":"2017","unstructured":"Zhao, J. et al. The prognostic implication of intraductal carcinoma of the prostate in metastatic castration-resistant prostate cancer and its potential predictive value in those treated with docetaxel or abiraterone as first-line therapy. Oncotarget 8, 55374\u201355383 https:\/\/doi.org\/10.18632\/oncotarget.19520 (2017).","journal-title":"Oncotarget"},{"key":"1194_CR89","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1002\/pros.24462","volume":"83","author":"Y Naito","year":"2023","unstructured":"Naito, Y. et al. Clinical utility of intraductal carcinoma of the prostate in treatment selection for metastatic hormone-sensitive prostate cancer. Prostate 83, 307\u2013315 https:\/\/doi.org\/10.1002\/pros.24462 (2023).","journal-title":"Prostate"},{"key":"1194_CR90","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-026-01143-2","author":"F Ditonno","year":"2026","unstructured":"Ditonno, F. et al. Prognostic value of cribriform pattern and intraductal carcinoma of the prostate after radical prostatectomy: a systematic review and meta-analysis using contemporary consensus recommendations. Prostate Cancer Prostatic Dis. https:\/\/doi.org\/10.1038\/s41391-026-01143-2 (2026).","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"1194_CR91","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1111\/cas.15392","volume":"113","author":"R Aizawa","year":"2022","unstructured":"Aizawa, R. et al. Clinical significance of IDC-P as predictive factor after intensity-modulated radiation therapy. Cancer Sci. 113, 2425\u20132433 https:\/\/doi.org\/10.1111\/cas.15392 (2022).","journal-title":"Cancer Sci."},{"key":"1194_CR92","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.clgc.2023.10.005","volume":"22","author":"K Miyajima","year":"2024","unstructured":"Miyajima, K. et al. Clinical significance of intraductal carcinoma of the prostate after high-dose brachytherapy with external beam radiation therapy: a single institution series and an updated meta-analysis. Clin. Genitourin. Cancer 22, 149\u2013156.e1 https:\/\/doi.org\/10.1016\/j.clgc.2023.10.005 (2024).","journal-title":"Clin. Genitourin. Cancer"},{"key":"1194_CR93","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.urolonc.2024.01.037","volume":"42","author":"Y Shi","year":"2024","unstructured":"Shi, Y. et al. Ductal, intraductal, and cribriform carcinoma of the prostate: molecular characteristics and clinical management. Urol. Oncol. 42, 144\u2013154 https:\/\/doi.org\/10.1016\/j.urolonc.2024.01.037 (2024).","journal-title":"Urol. Oncol."},{"key":"1194_CR94","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.clgc.2019.04.009","volume":"17","author":"S Knipper","year":"2019","unstructured":"Knipper, S. et al. Contemporary comparison of clinicopathologic characteristics and survival outcomes of prostate ductal carcinoma and acinar adenocarcinoma: a population-based study. Clin. Genitourin. Cancer 17, 231\u2013237.e2 https:\/\/doi.org\/10.1016\/j.clgc.2019.04.009 (2019).","journal-title":"Clin. Genitourin. Cancer"},{"key":"1194_CR95","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.2147\/OTT.S47165","volume":"6","author":"J Sha","year":"2013","unstructured":"Sha, J. et al. Ductal adenocarcinoma of the prostate: immunohistochemical findings and clinical significance. Onco Targets Ther. 6, 1501\u20131506 https:\/\/doi.org\/10.2147\/OTT.S47165 (2013).","journal-title":"Onco Targets Ther."},{"key":"1194_CR96","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1016\/j.juro.2010.08.017","volume":"184","author":"TM Morgan","year":"2010","unstructured":"Morgan, T. M., Welty, C. J., Vakar-Lopez, F., Lin, D. W. & Wright, J. L. Ductal adenocarcinoma of the prostate: increased mortality risk and decreased serum prostate specific antigen. J. Urol. 184, 2303\u20132307 https:\/\/doi.org\/10.1016\/j.juro.2010.08.017 (2010).","journal-title":"J. Urol."},{"key":"1194_CR97","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1007\/s00261-022-03454-z","volume":"47","author":"H Edo","year":"2022","unstructured":"Edo, H. et al. Magnetic resonance imaging findings of pure prostatic ductal adenocarcinomas: a case series. Abdom. Radiol. 47, 1929\u20131938 https:\/\/doi.org\/10.1007\/s00261-022-03454-z (2022).","journal-title":"Abdom. Radiol."},{"key":"1194_CR98","doi-asserted-by":"publisher","first-page":"3667","DOI":"10.1002\/cncr.32957","volume":"126","author":"WKB Ranasinghe","year":"2020","unstructured":"Ranasinghe, W. K. B. et al. Patterns of metastases of prostatic ductal adenocarcinoma. Cancer 126, 3667\u20133673 https:\/\/doi.org\/10.1002\/cncr.32957 (2020).","journal-title":"Cancer"},{"key":"1194_CR99","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.euros.2022.10.013","volume":"46","author":"Y Wei","year":"2022","unstructured":"Wei, Y. et al. Comparison of survival outcomes and risk factors between ductal carcinoma of the prostate and acinar adenocarcinoma of the prostate: a population-based propensity score-matching study. Eur. Urol. Open Sci. 46, 88\u201395 https:\/\/doi.org\/10.1016\/j.euros.2022.10.013 (2022).","journal-title":"Eur. Urol. Open Sci."},{"key":"1194_CR100","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1097\/CU9.0000000000000118","volume":"16","author":"S Cozzi","year":"2022","unstructured":"Cozzi, S. et al. Ductal prostate cancer: clinical features and outcomes from a multicenter retrospective analysis and overview of the current literature. Curr. Urol. 16, 218\u2013226 https:\/\/doi.org\/10.1097\/CU9.0000000000000118 (2022).","journal-title":"Curr. Urol."},{"key":"1194_CR101","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1002\/pros.24304","volume":"82","author":"C Lindh","year":"2022","unstructured":"Lindh, C. et al. Ductal and acinar components of mixed prostatic adenocarcinoma frequently have a common clonal origin. Prostate 82, 576\u2013583 https:\/\/doi.org\/10.1002\/pros.24304 (2022).","journal-title":"Prostate"},{"key":"1194_CR102","doi-asserted-by":"publisher","first-page":"3894","DOI":"10.1158\/1078-0432.CCR-23-3403","volume":"30","author":"AT Lenis","year":"2024","unstructured":"Lenis, A. T. et al. Microsatellite instability, tumor mutational burden, and response to immune checkpoint blockade in patients with prostate cancer. Clin. Cancer Res. 30, 3894\u20133903 https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-3403 (2024).","journal-title":"Clin. Cancer Res."},{"key":"1194_CR103","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1158\/1078-0432.CCR-24-1210","volume":"31","author":"CS McNevin","year":"2025","unstructured":"McNevin, C. S. et al. Prevalence of mismatch repair deficiency in primary prostate cancer in a large prospective cohort. Clin. Cancer Res. 31, 1746\u20131753 https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-1210 (2025).","journal-title":"Clin. Cancer Res."},{"key":"1194_CR104","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-65681-2","volume":"14","author":"K Kurokawa","year":"2024","unstructured":"Kurokawa, K. et al. Implications of unconventional histological subtypes on magnetic resonance imaging and oncological outcomes in patients who have undergone radical prostatectomy. Sci. Rep. 14, 14868 https:\/\/doi.org\/10.1038\/s41598-024-65681-2 (2024).","journal-title":"Sci. Rep."},{"key":"1194_CR105","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.eururo.2020.11.015","volume":"79","author":"W Ranasinghe","year":"2021","unstructured":"Ranasinghe, W. et al. Ductal prostate cancers demonstrate poor outcomes with conventional therapies. Eur. Urol. 79, 298\u2013306 https:\/\/doi.org\/10.1016\/j.eururo.2020.11.015 (2021).","journal-title":"Eur. Urol."},{"key":"1194_CR106","doi-asserted-by":"publisher","first-page":"366.e11","DOI":"10.1016\/j.urolonc.2020.11.013","volume":"39","author":"C Bronkema","year":"2021","unstructured":"Bronkema, C. et al. Impact of treatment modality on overall survival in localized ductal prostate adenocarcinoma: a National Cancer Database analysis. Urol. Oncol. 39, 366.e11\u2013366.e18 https:\/\/doi.org\/10.1016\/j.urolonc.2020.11.013 (2021).","journal-title":"Urol. Oncol."},{"key":"1194_CR107","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1002\/pros.24869","volume":"85","author":"Y Shi","year":"2025","unstructured":"Shi, Y. et al. The prognostic value of the prostate adenocarcinoma with ductal feature in patients with advanced prostate cancer treated with abiraterone acetate. Prostate 85, 659\u2013669 https:\/\/doi.org\/10.1002\/pros.24869 (2025).","journal-title":"Prostate"},{"key":"1194_CR108","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.ejca.2020.12.030","volume":"148","author":"K Chow","year":"2021","unstructured":"Chow, K. et al. Ductal variant prostate carcinoma is associated with a significantly shorter metastasis-free survival. Eur. J. Cancer 148, 440\u2013450 https:\/\/doi.org\/10.1016\/j.ejca.2020.12.030 (2021).","journal-title":"Eur. J. Cancer"},{"key":"1194_CR109","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/S1470-2045(24)00440-6","volume":"25","author":"AA Azad","year":"2024","unstructured":"Azad, A. A. et al. Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study. Lancet Oncol. 25, 1267\u20131276 https:\/\/doi.org\/10.1016\/S1470-2045(24)00440-6 (2024).","journal-title":"Lancet Oncol."},{"key":"1194_CR110","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3729-z","volume":"17","author":"HK Tsai","year":"2017","unstructured":"Tsai, H. K. et al. Gene expression signatures of neuroendocrine prostate cancer and primary small cell prostatic carcinoma. BMC Cancer 17, 759 https:\/\/doi.org\/10.1186\/s12885-017-3729-z (2017).","journal-title":"BMC Cancer"},{"key":"1194_CR111","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-024-05983-0","volume":"150","author":"D Heimd\u00f6rfer","year":"2024","unstructured":"Heimd\u00f6rfer, D., Artamonova, N., Culig, Z. & Heidegger, I. Unraveling molecular characteristics and tumor microenvironment dynamics of neuroendocrine prostate cancer. J. Cancer Res. Clin. Oncol. 150, 462 https:\/\/doi.org\/10.1007\/s00432-024-05983-0 (2024).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"1194_CR112","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1002\/bco2.212","volume":"4","author":"J Chen","year":"2023","unstructured":"Chen, J. et al. Genomic alterations in neuroendocrine prostate cancer: a systematic review and meta-analysis. BJUI Compass 4, 256\u2013265 https:\/\/doi.org\/10.1002\/bco2.212 (2023).","journal-title":"BJUI Compass"},{"key":"1194_CR113","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13225765","volume":"13","author":"A Taher","year":"2021","unstructured":"Taher, A. et al. Imaging of neuroendocrine prostatic carcinoma. Cancers 13, 5765 https:\/\/doi.org\/10.3390\/cancers13225765 (2021).","journal-title":"Cancers"},{"key":"1194_CR114","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.annonc.2020.02.002","volume":"31","author":"R Ge","year":"2020","unstructured":"Ge, R. et al. Epigenetic modulations and lineage plasticity in advanced prostate cancer. Ann. Oncol. 31, 470\u2013479 https:\/\/doi.org\/10.1016\/j.annonc.2020.02.002 (2020).","journal-title":"Ann. Oncol."},{"key":"1194_CR115","doi-asserted-by":"publisher","first-page":"13673","DOI":"10.3390\/ijms241813673","volume":"24","author":"I Zamora","year":"2023","unstructured":"Zamora, I., Freeman, M. R., Enc\u00edo, I. J. & Rotinen, M. Targeting key players of neuroendocrine differentiation in prostate cancer. Int. J. Mol. Sci. 24, 13673 https:\/\/doi.org\/10.3390\/ijms241813673 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"1194_CR116","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14040892","volume":"14","author":"M Christenson","year":"2022","unstructured":"Christenson, M., Song, C. S., Liu, Y. G. & Chatterjee, B. Precision targets for intercepting the lethal progression of prostate cancer: potential avenues for personalized therapy. Cancers 14, 892 https:\/\/doi.org\/10.3390\/cancers14040892 (2022).","journal-title":"Cancers"},{"key":"1194_CR117","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1341794","volume":"14","author":"N Nguyen","year":"2024","unstructured":"Nguyen, N. et al. A systematic review of primary large cell neuroendocrine carcinoma of the prostate. Front. Oncol. 14, 1341794 https:\/\/doi.org\/10.3389\/fonc.2024.1341794 (2024).","journal-title":"Front. Oncol."},{"key":"1194_CR118","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-020-01003-9","volume":"23","author":"Y Yamada","year":"2021","unstructured":"Yamada, Y. & Beltran, H. Clinical and biological features of neuroendocrine prostate cancer. Curr. Oncol. Rep. 23, 15 https:\/\/doi.org\/10.1007\/s11912-020-01003-9 (2021).","journal-title":"Curr. Oncol. Rep."},{"key":"1194_CR119","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23780-y","volume":"12","author":"NJ Brady","year":"2021","unstructured":"Brady, N. J. et al. Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer. Nat. Commun. 12, 3372 https:\/\/doi.org\/10.1038\/s41467-021-23780-y (2021).","journal-title":"Nat. Commun."},{"key":"1194_CR120","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1200\/JCO.19.02757","volume":"38","author":"EJ Trabulsi","year":"2020","unstructured":"Trabulsi, E. J. et al. Optimum imaging strategies for advanced prostate cancer: ASCO Guideline. J. Clin. Oncol. 38, 1963\u20131996 https:\/\/doi.org\/10.1200\/JCO.19.02757 (2020).","journal-title":"J. Clin. Oncol."},{"key":"1194_CR121","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.778758","volume":"12","author":"J Yao","year":"2021","unstructured":"Yao, J. et al. Neuroendocrine carcinoma as an independent prognostic factor for patients with prostate cancer: a population-based study. Front. Endocrinol. 12, 778758 https:\/\/doi.org\/10.3389\/fendo.2021.778758 (2021).","journal-title":"Front. Endocrinol."},{"key":"1194_CR122","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1002\/pros.24664","volume":"84","author":"I de Kouchkovsky","year":"2024","unstructured":"de Kouchkovsky, I., Chan, E., Schloss, C., Poehlein, C. & Aggarwal, R. Diagnosis and management of neuroendocrine prostate cancer. Prostate 84, 426\u2013440 https:\/\/doi.org\/10.1002\/pros.24664 (2024).","journal-title":"Prostate"},{"key":"1194_CR123","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/s41585-021-00490-0","volume":"18","author":"Y Wang","year":"2021","unstructured":"Wang, Y., Ci, X., Choi, S. Y. C., Crea, F. & Lin, D. Molecular events in neuroendocrine prostate cancer development. Nat. Rev. Urol. 18, 581\u2013596 https:\/\/doi.org\/10.1038\/s41585-021-00490-0 (2021).","journal-title":"Nat. Rev. Urol."},{"key":"1194_CR124","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s00345-022-04248-0","volume":"41","author":"G Ploussard","year":"2023","unstructured":"Ploussard, G. et al. Chromogranin A: a useful biomarker in castration-resistant prostate cancer. World J. Urol. 41, 361\u2013369 https:\/\/doi.org\/10.1007\/s00345-022-04248-0 (2023).","journal-title":"World J. Urol."},{"key":"1194_CR125","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1002\/pros.24035","volume":"80","author":"H Kaur","year":"2020","unstructured":"Kaur, H. et al. Neuroendocrine differentiation in usual-type prostatic adenocarcinoma: molecular characterization and clinical significance. Prostate 80, 1012\u20131023 https:\/\/doi.org\/10.1002\/pros.24035 (2020).","journal-title":"Prostate"},{"key":"1194_CR126","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1093\/oncolo\/oyad344","volume":"29","author":"AV Serritella","year":"2024","unstructured":"Serritella, A. V. et al. Large cell neuroendocrine prostate cancer: large is not small. Oncologist 29, 185\u2013189 https:\/\/doi.org\/10.1093\/oncolo\/oyad344 (2024).","journal-title":"Oncologist"},{"key":"1194_CR127","doi-asserted-by":"publisher","DOI":"10.1172\/JCI164611","volume":"132","author":"F Karzai","year":"2022","unstructured":"Karzai, F. & Madan, R. A. Deciphering the enigma of neuroendocrine prostate cancer. J. Clin. Invest. 132, e164611 https:\/\/doi.org\/10.1172\/JCI164611 (2022).","journal-title":"J. Clin. Invest."},{"key":"1194_CR128","doi-asserted-by":"publisher","DOI":"10.1530\/JOE-22-0211","volume":"256","author":"L Brady","year":"2023","unstructured":"Brady, L. & Nelson, P. S. RISING STARS: Heterogeneity and the tumor microenvironment in neuroendocrine prostate cancer. J. Endocrinol. 256, e220211 https:\/\/doi.org\/10.1530\/JOE-22-0211 (2023).","journal-title":"J. Endocrinol."},{"key":"1194_CR129","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-026-69308-0","volume":"17","author":"R Singh","year":"2026","unstructured":"Singh, R. et al. Crosstalk between EZH2 and DNA methylation mediates neuroendocrine prostate cancer lineage plasticity. Nat. Commun. 17, 2992 https:\/\/doi.org\/10.1038\/s41467-026-69308-0 (2026).","journal-title":"Nat. Commun."},{"key":"1194_CR130","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22139-7","volume":"12","author":"SC Baca","year":"2021","unstructured":"Baca, S. C. et al. Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer. Nat. Commun. 12, 1979 https:\/\/doi.org\/10.1038\/s41467-021-22139-7 (2021).","journal-title":"Nat. Commun."},{"key":"1194_CR131","doi-asserted-by":"publisher","first-page":"T67","DOI":"10.1530\/ERC-21-0140","volume":"28","author":"H Beltran","year":"2021","unstructured":"Beltran, H. & Demichelis, F. Therapy considerations in neuroendocrine prostate cancer: what next? Endocr. Relat. Cancer 28, T67\u2013T78 https:\/\/doi.org\/10.1530\/ERC-21-0140 (2021).","journal-title":"Endocr. Relat. Cancer"},{"key":"1194_CR132","doi-asserted-by":"publisher","first-page":"e352","DOI":"10.1016\/j.clgc.2021.05.005","volume":"19","author":"V Chau","year":"2021","unstructured":"Chau, V. et al. Anaplastic features in advanced prostate cancer with and without DNA damage repair mutations. Clin. Genitourin. Cancer 19, e352\u2013e359 https:\/\/doi.org\/10.1016\/j.clgc.2021.05.005 (2021).","journal-title":"Clin. Genitourin. Cancer"},{"key":"1194_CR133","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/0090-4295(92)90235-o","volume":"39","author":"SR Moore","year":"1992","unstructured":"Moore, S. R., Reinberg, Y. & Zhang, G. Small cell carcinoma of prostate: effectiveness of hormonal versus chemotherapy. Urology 39, 411\u2013416 https:\/\/doi.org\/10.1016\/0090-4295(92)90235-o (1992).","journal-title":"Urology"},{"key":"1194_CR134","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/nrurol.2014.21","volume":"11","author":"R Nadal","year":"2014","unstructured":"Nadal, R., Schweizer, M., Kryvenko, O. N., Epstein, J. I. & Eisenberger, M. A. Small cell carcinoma of the prostate. Nat. Rev. Urol. 11, 213\u2013219 https:\/\/doi.org\/10.1038\/nrurol.2014.21 (2014).","journal-title":"Nat. Rev. Urol."},{"key":"1194_CR135","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1159\/000519861","volume":"100","author":"V Achard","year":"2022","unstructured":"Achard, V., Putora, P. M., Omlin, A., Zilli, T. & Fischer, S. Metastatic prostate cancer: treatment options. Oncology 100, 48\u201359 https:\/\/doi.org\/10.1159\/000519861 (2022).","journal-title":"Oncology"},{"key":"1194_CR136","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_430336","volume":"44","author":"RS Liao","year":"2024","unstructured":"Liao, R. S. et al. Emerging insights in small-cell carcinoma of the genitourinary tract: from diagnosis to novel therapeutic horizons. Am. Soc. Clin. Oncol. Educ. Book 44, e430336 https:\/\/doi.org\/10.1200\/EDBK_430336 (2024).","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"1194_CR137","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aav0891","volume":"11","author":"L Puca","year":"2019","unstructured":"Puca, L. et al. Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer. Sci. Transl. Med. 11, eaav0891 https:\/\/doi.org\/10.1126\/scitranslmed.aav0891 (2019).","journal-title":"Sci. Transl. Med."},{"key":"1194_CR138","doi-asserted-by":"publisher","first-page":"3854","DOI":"10.1158\/1078-0432.CCR-25-1211","volume":"31","author":"R Aggarwal","year":"2025","unstructured":"Aggarwal, R. et al. Safety and efficacy of tarlatamab in patients with neuroendocrine prostate cancer: results from the phase 1b DeLLpro-300 study. Clin. Cancer Res. 31, 3854\u20133863 https:\/\/doi.org\/10.1158\/1078-0432.CCR-25-1211 (2025).","journal-title":"Clin. Cancer Res."},{"key":"1194_CR139","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1158\/0008-5472.CAN-22-1433","volume":"83","author":"J Chou","year":"2023","unstructured":"Chou, J. et al. Immunotherapeutic targeting and PET imaging of DLL3 in small-cell neuroendocrine prostate cancer. Cancer Res. 83, 301\u2013315 https:\/\/doi.org\/10.1158\/0008-5472.CAN-22-1433 (2023).","journal-title":"Cancer Res."},{"key":"1194_CR140","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1158\/1078-0432.CCR-23-2978","volume":"30","author":"T Dorff","year":"2024","unstructured":"Dorff, T. et al. A phase I study of acapatamab, a half-life extended, PSMA-targeting bispecific T-cell engager for metastatic castration-resistant prostate cancer. Clin. Cancer Res. 30, 1488\u20131500 https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-2978 (2024).","journal-title":"Clin. Cancer Res."},{"key":"1194_CR141","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-51156-5","volume":"15","author":"VB Venkadakrishnan","year":"2024","unstructured":"Venkadakrishnan, V. B. et al. Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypes. Nat. Commun. 15, 6779 https:\/\/doi.org\/10.1038\/s41467-024-51156-5 (2024).","journal-title":"Nat. Commun."},{"key":"1194_CR142","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.eururo.2022.09.004","volume":"83","author":"C Guo","year":"2023","unstructured":"Guo, C. et al. B7-H3 as a therapeutic target in advanced prostate cancer. Eur. Urol. 83, 224\u2013238 https:\/\/doi.org\/10.1016\/j.eururo.2022.09.004 (2023).","journal-title":"Eur. Urol."},{"key":"1194_CR143","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1158\/1078-0432.CCR-22-1305","volume":"29","author":"JM Sperger","year":"2023","unstructured":"Sperger, J. M. et al. Expression and therapeutic targeting of TROP-2 in treatment-resistant prostate cancer. Clin. Cancer Res. 29, 2324\u20132335 https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-1305 (2023).","journal-title":"Clin. Cancer Res."},{"key":"1194_CR144","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/s41585-025-01014-w","volume":"22","author":"C Boixareu","year":"2025","unstructured":"Boixareu, C., Taha, T., Venkadakrishnan, V. B., de Bono, J. & Beltran, H. Targeting the tumour cell surface in advanced prostate cancer. Nat. Rev. Urol. 22, 569\u2013589 https:\/\/doi.org\/10.1038\/s41585-025-01014-w (2025).","journal-title":"Nat. Rev. Urol."},{"key":"1194_CR145","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1007\/s11864-023-01121-z","volume":"24","author":"F Davoudi","year":"2023","unstructured":"Davoudi, F. et al. Genomic and phenotypic biomarkers for precision medicine guidance in advanced prostate cancer. Curr. Treat. Options Oncol. 24, 1451\u20131471 https:\/\/doi.org\/10.1007\/s11864-023-01121-z (2023).","journal-title":"Curr. Treat. Options Oncol."},{"key":"1194_CR146","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-26-0268","volume":"33","author":"S Choi","year":"2026","unstructured":"Choi, S. et al. Epidemiology and overall survival of de novo and transformed neuroendocrine prostate cancer: a two-nation population-based study of 1,465 patients from the United States and England. Endocr. Relat. Cancer 33, e260268 https:\/\/doi.org\/10.1530\/ERC-26-0268 (2026).","journal-title":"Endocr. Relat. Cancer"},{"key":"1194_CR147","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.21873\/anticanres.15699","volume":"42","author":"H Iwamoto","year":"2022","unstructured":"Iwamoto, H. et al. Treatment outcomes in neuroendocrine prostate cancer. Anticancer Res. 42, 2167\u20132176 https:\/\/doi.org\/10.21873\/anticanres.15699 (2022).","journal-title":"Anticancer Res."},{"key":"1194_CR148","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000025237","volume":"100","author":"J Zhu","year":"2021","unstructured":"Zhu, J. et al. Clinicopathological characteristics and survival outcomes in neuroendocrine prostate cancer: a population-based study. Medicine 100, e25237 https:\/\/doi.org\/10.1097\/MD.0000000000025237 (2021).","journal-title":"Medicine"},{"key":"1194_CR149","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00280-023-04604-w","volume":"93","author":"M Catalano","year":"2024","unstructured":"Catalano, M. et al. Platinum-based chemotherapy in metastatic prostate cancer: what possibilities? Cancer Chemother. Pharmacol. 93, 1\u20139 https:\/\/doi.org\/10.1007\/s00280-023-04604-w (2024).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"1194_CR150","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1097\/01.pas.0000209838.92842.bf","volume":"30","author":"DE Hansel","year":"2006","unstructured":"Hansel, D. E. & Epstein, J. I. Sarcomatoid carcinoma of the prostate: a study of 42 cases. Am. J. Surg. Pathol. 30, 1316\u20131321 https:\/\/doi.org\/10.1097\/01.pas.0000209838.92842.bf (2006).","journal-title":"Am. J. Surg. Pathol."},{"key":"1194_CR151","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1148\/rg.2016150226","volume":"36","author":"Y Li","year":"2016","unstructured":"Li, Y. et al. Beyond prostate adenocarcinoma: expanding the differential diagnosis in prostate pathologic conditions. Radiographics 36, 1055\u20131075 https:\/\/doi.org\/10.1148\/rg.2016150226 (2016).","journal-title":"Radiographics"},{"key":"1194_CR152","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.urology.2015.06.011","volume":"86","author":"MC Markowski","year":"2015","unstructured":"Markowski, M. C., Eisenberger, M. A., Zahurak, M., Epstein, J. I. & Paller, C. J. Sarcomatoid carcinoma of the prostate: retrospective review of a case series from the Johns Hopkins Hospital. Urology 86, 539\u2013543 https:\/\/doi.org\/10.1016\/j.urology.2015.06.011 (2015).","journal-title":"Urology"},{"key":"1194_CR153","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/j.1365-2559.2011.04039.x","volume":"60","author":"PA Humphrey","year":"2012","unstructured":"Humphrey, P. A. Histological variants of prostatic carcinoma and their significance. Histopathology 60, 59\u201374 https:\/\/doi.org\/10.1111\/j.1365-2559.2011.04039.x (2012).","journal-title":"Histopathology"},{"key":"1194_CR154","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s40261-022-01178-y","volume":"42","author":"A Figueiredo","year":"2022","unstructured":"Figueiredo, A. et al. Nonmetastatic castration-resistant prostate cancer: current challenges and trends. Clin. Drug Investig. 42, 631\u2013642 https:\/\/doi.org\/10.1007\/s40261-022-01178-y (2022).","journal-title":"Clin. Drug Investig."},{"key":"1194_CR155","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2025.105988","volume":"167","author":"B Tekin","year":"2026","unstructured":"Tekin, B. et al. Sarcomatoid carcinoma of the prostate \u2014 a single institution experience with emphasis on molecular genetic findings. Hum. Pathol. 167, 105988 https:\/\/doi.org\/10.1016\/j.humpath.2025.105988 (2026).","journal-title":"Hum. Pathol."},{"key":"1194_CR156","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1158\/1078-0432.CCR-13-1982","volume":"20","author":"HL Tan","year":"2014","unstructured":"Tan, H. L. et al. Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma. Clin. Cancer Res. 20, 890\u2013903 https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-1982 (2014).","journal-title":"Clin. Cancer Res."},{"key":"1194_CR157","doi-asserted-by":"publisher","first-page":"3948","DOI":"10.1158\/1078-0432.CCR-23-1393","volume":"29","author":"A Chehrazi-Raffle","year":"2023","unstructured":"Chehrazi-Raffle, A. et al. Unique spectrum of activating BRAF alterations in prostate cancer. Clin. Cancer Res. 29, 3948\u20133957 https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-1393 (2023).","journal-title":"Clin. Cancer Res."},{"key":"1194_CR158","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1002\/pros.24758","volume":"84","author":"Y Wei","year":"2024","unstructured":"Wei, Y. et al. Analysis of three primary prostatic sarcoma cases and literature review. Prostate 84, 1218\u20131223 https:\/\/doi.org\/10.1002\/pros.24758 (2024).","journal-title":"Prostate"},{"key":"1194_CR159","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1002\/pros.23375","volume":"77","author":"B De Bari","year":"2017","unstructured":"De Bari, B. et al. Adult prostatic sarcoma: a contemporary multicenter Rare Cancer Network study. Prostate 77, 1160\u20131166 https:\/\/doi.org\/10.1002\/pros.23375 (2017).","journal-title":"Prostate"},{"key":"1194_CR160","doi-asserted-by":"publisher","first-page":"6030","DOI":"10.1002\/cam4.1872","volume":"7","author":"JD Tward","year":"2018","unstructured":"Tward, J. D. et al. Demographics, stage distribution, and relative roles of surgery and radiotherapy on survival of persons with primary prostate sarcomas. Cancer Med. 7, 6030\u20136039 https:\/\/doi.org\/10.1002\/cam4.1872 (2018).","journal-title":"Cancer Med."},{"key":"1194_CR161","doi-asserted-by":"publisher","first-page":"4178","DOI":"10.1016\/j.asjsur.2022.11.004","volume":"46","author":"J Zhao","year":"2023","unstructured":"Zhao, J. et al. The therapeutic efficacy of radical prostatectomy and external beam radiation therapy in patients with different pathological patterns of prostate cancer. Asian J. Surg. 46, 4178\u20134185 https:\/\/doi.org\/10.1016\/j.asjsur.2022.11.004 (2023).","journal-title":"Asian J. Surg."},{"key":"1194_CR162","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1094943","volume":"13","author":"J Wang","year":"2023","unstructured":"Wang, J., Zhang, C., Chen, B. & Wu, Q. Basal cell carcinoma of the prostate with squamous metaplasia: a case report and literature review. Front. Oncol. 13, 1094943 https:\/\/doi.org\/10.3389\/fonc.2023.1094943 (2023).","journal-title":"Front. Oncol."},{"key":"1194_CR163","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1093\/ajcp\/62.5.639","volume":"62","author":"K Frankel","year":"1974","unstructured":"Frankel, K. & Craig, J. R. Adenoid cystic carcinoma of the prostate. Report of a case. Am. J. Clin. Pathol. 62, 639\u2013645 https:\/\/doi.org\/10.1093\/ajcp\/62.5.639 (1974).","journal-title":"Am. J. Clin. Pathol."},{"key":"1194_CR164","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1007\/s10147-010-0082-5","volume":"15","author":"K Komura","year":"2010","unstructured":"Komura, K. et al. Basal cell carcinoma of the prostate: unusual subtype of prostatic carcinoma. Int. J. Clin. Oncol. 15, 594\u2013600 https:\/\/doi.org\/10.1007\/s10147-010-0082-5 (2010).","journal-title":"Int. J. Clin. Oncol."},{"key":"1194_CR165","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.humpath.2015.02.004","volume":"46","author":"NB Simper","year":"2015","unstructured":"Simper, N. B. et al. Basal cell carcinoma of the prostate is an aggressive tumor with frequent loss of PTEN expression and overexpression of EGFR. Hum. Pathol. 46, 805\u2013812 https:\/\/doi.org\/10.1016\/j.humpath.2015.02.004 (2015).","journal-title":"Hum. Pathol."},{"key":"1194_CR166","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1097\/01.pas.0000213395.42075.86","volume":"31","author":"TZ Ali","year":"2007","unstructured":"Ali, T. Z. & Epstein, J. I. Basal cell carcinoma of the prostate: a clinicopathologic study of 29 cases. Am. J. Surg. Pathol. 31, 697\u2013705 https:\/\/doi.org\/10.1097\/01.pas.0000213395.42075.86 (2007).","journal-title":"Am. J. Surg. Pathol."},{"key":"1194_CR167","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1097\/00000478-200312000-00004","volume":"27","author":"KA Iczkowski","year":"2003","unstructured":"Iczkowski, K. A. et al. Adenoid cystic\/basal cell carcinoma of the prostate: clinicopathologic findings in 19 cases. Am. J. Surg. Pathol. 27, 1523\u20131529 https:\/\/doi.org\/10.1097\/00000478-200312000-00004 (2003).","journal-title":"Am. J. Surg. Pathol."},{"key":"1194_CR168","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1097\/01.pas.0000138180.95581.e1","volume":"28","author":"JK McKenney","year":"2004","unstructured":"McKenney, J. K. et al. Basal cell proliferations of the prostate other than usual basal cell hyperplasia: a clinicopathologic study of 23 cases, including four carcinomas, with a proposed classification. Am. J. Surg. Pathol. 28, 1289\u20131298 https:\/\/doi.org\/10.1097\/01.pas.0000138180.95581.e1 (2004).","journal-title":"Am. J. Surg. Pathol."},{"key":"1194_CR169","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1046\/j.1365-2559.1996.d01-477.x","volume":"28","author":"N Hasan","year":"1996","unstructured":"Hasan, N. & Dodd, S. Basal cell carcinoma of the prostate. Histopathology 28, 571 https:\/\/doi.org\/10.1046\/j.1365-2559.1996.d01-477.x (1996).","journal-title":"Histopathology"},{"key":"1194_CR170","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1016\/s0046-8177(98)90014-4","volume":"29","author":"XJ Yang","year":"1998","unstructured":"Yang, X. J., McEntee, M. & Epstein, J. I. Distinction of basaloid carcinoma of the prostate from benign basal cell lesions by using immunohistochemistry for bcl-2 and Ki-67. Hum. Pathol. 29, 1447\u20131450 https:\/\/doi.org\/10.1016\/s0046-8177(98)90014-4 (1998).","journal-title":"Hum. Pathol."},{"key":"1194_CR171","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.ajpath.2022.09.010","volume":"193","author":"JY Low","year":"2023","unstructured":"Low, J. Y. et al. Genomic characterization of prostatic basal cell carcinoma. Am. J. Pathol. 193, 4\u201310 https:\/\/doi.org\/10.1016\/j.ajpath.2022.09.010 (2023).","journal-title":"Am. J. Pathol."},{"key":"1194_CR172","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1002\/path.4186","volume":"230","author":"C Weier","year":"2013","unstructured":"Weier, C. et al. Nucleotide resolution analysis of TMPRSS2 and ERG rearrangements in prostate cancer. J. Pathol. 230, 174\u2013183 https:\/\/doi.org\/10.1002\/path.4186 (2013).","journal-title":"J. Pathol."},{"key":"1194_CR173","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1038\/s41379-019-0297-6","volume":"32","author":"MJ Magers","year":"2019","unstructured":"Magers, M. J. et al. MYB-NFIB gene fusion in prostatic basal cell carcinoma: clinicopathologic correlates and comparison with basal cell adenoma and florid basal cell hyperplasia. Mod. Pathol. 32, 1666\u20131674 https:\/\/doi.org\/10.1038\/s41379-019-0297-6 (2019).","journal-title":"Mod. Pathol."},{"key":"1194_CR174","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7819-11-193","volume":"11","author":"K Chang","year":"2013","unstructured":"Chang, K. et al. Basal cell carcinoma of the prostate: clinicopathologic analysis of three cases and a review of the literature. World J. Surg. Oncol. 11, 193 https:\/\/doi.org\/10.1186\/1477-7819-11-193 (2013).","journal-title":"World J. Surg. Oncol."},{"key":"1194_CR175","doi-asserted-by":"publisher","DOI":"10.1002\/iju5.12145","volume":"3","author":"Y Funahashi","year":"2020","unstructured":"Funahashi, Y. Editorial comment to primary basal cell carcinoma of the prostate with concurrent adenocarcinoma. IJU Case Rep. 3, 61 https:\/\/doi.org\/10.1002\/iju5.12145 (2020).","journal-title":"IJU Case Rep."},{"key":"1194_CR176","doi-asserted-by":"publisher","DOI":"10.1016\/j.eucr.2024.102742","volume":"57","author":"H Jiang","year":"2024","unstructured":"Jiang, H. Tislelizumab: an effective anti-PD-1 antibody for the treatment of advanced basal cell carcinoma of the prostate. Urol. Case Rep. 57, 102742 https:\/\/doi.org\/10.1016\/j.eucr.2024.102742 (2024).","journal-title":"Urol. Case Rep."},{"key":"1194_CR177","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1097\/MOU.0000000000001007","volume":"32","author":"K Rebhan","year":"2022","unstructured":"Rebhan, K., Wasinger, G., Hassler, M. R., Shariat, S. F. & Comp\u00e9rat, E. M. Basal cell carcinoma of the prostate: a case report responding to the FGFR inhibitor pemigatinib and literature review. Curr. Opin. Urol. 32, 358\u2013363 https:\/\/doi.org\/10.1097\/MOU.0000000000001007 (2022).","journal-title":"Curr. Opin. Urol."},{"key":"1194_CR178","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.ijrobp.2024.09.034","volume":"121","author":"W Su","year":"2025","unstructured":"Su, W. et al. Definitive radiation therapy is a viable treatment for locally advanced basal cell carcinoma otherwise requiring radical or disfiguring resection. Int. J. Radiat. Oncol. Biol. Phys. 121, 677\u2013683 https:\/\/doi.org\/10.1016\/j.ijrobp.2024.09.034 (2025).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"1194_CR179","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1002\/pros.24521","volume":"83","author":"JQ Trinh","year":"2023","unstructured":"Trinh, J. Q., Lele, S. M. & Teply, B. A. A case of metastatic adenoid cystic (basal cell) carcinoma of the prostate: systemic therapy for a rare disease. Prostate 83, 814\u2013819 https:\/\/doi.org\/10.1002\/pros.24521 (2023).","journal-title":"Prostate"},{"key":"1194_CR180","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2025.110987","volume":"44","author":"R Watanabe","year":"2026","unstructured":"Watanabe, R. et al. Molecular pathology of rare histologic variants and treatment-resistant lineages of prostate cancer. Urol. Oncol. 44, 110987 https:\/\/doi.org\/10.1016\/j.urolonc.2025.110987 (2026).","journal-title":"Urol. Oncol."},{"key":"1194_CR181","doi-asserted-by":"publisher","DOI":"10.1007\/s11764-025-01896-0","author":"T Farrugia","year":"2025","unstructured":"Farrugia, T. et al. \u2018I knew I had to drive my own bus\u2019: perspectives of patients and healthcare professionals on improving information provision to rare cancer survivors. J. Cancer Surviv. https:\/\/doi.org\/10.1007\/s11764-025-01896-0 (2025).","journal-title":"J. Cancer Surviv."},{"key":"1194_CR182","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/pcan.2012.4","volume":"15","author":"DM Marcus","year":"2012","unstructured":"Marcus, D. M., Goodman, M., Jani, A. B., Osunkoya, A. O. & Rossi, P. J. A comprehensive review of incidence and survival in patients with rare histological variants of prostate cancer in the United States from 1973 to 2008. Prostate Cancer Prostatic Dis. 15, 283\u2013288 https:\/\/doi.org\/10.1038\/pcan.2012.4 (2012).","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"1194_CR183","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.eururo.2015.05.046","volume":"69","author":"G Gandaglia","year":"2016","unstructured":"Gandaglia, G. et al. Prostate cancer registries: current status and future directions. Eur. Urol. 69, 998\u20131012 https:\/\/doi.org\/10.1016\/j.eururo.2015.05.046 (2016).","journal-title":"Eur. Urol."},{"key":"1194_CR184","doi-asserted-by":"publisher","DOI":"10.1200\/GO.22.00154","volume":"8","author":"LA Mucci","year":"2022","unstructured":"Mucci, L. A. et al. IRONMAN: a novel international registry of men with advanced prostate cancer. JCO Glob. Oncol. 8, e2200154 https:\/\/doi.org\/10.1200\/GO.22.00154 (2022).","journal-title":"JCO Glob. Oncol."},{"key":"1194_CR185","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/pros.24650","volume":"84","author":"CJ Paller","year":"2024","unstructured":"Paller, C. J. et al. PROMISE Registry: a prostate cancer registry of outcomes and germline mutations for improved survival and treatment effectiveness. Prostate 84, 292\u2013302 https:\/\/doi.org\/10.1002\/pros.24650 (2024).","journal-title":"Prostate"},{"key":"1194_CR186","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04923178 (2026)."},{"key":"1194_CR187","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT03866382 (2026)."},{"key":"1194_CR188","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1382376","volume":"14","author":"L Zhu","year":"2024","unstructured":"Zhu, L. et al. Case report: pyrotinib in the treatment of advanced scrotal EMPD combined with sweat gland carcinoma. Front. Oncol. 14, 1382376 https:\/\/doi.org\/10.3389\/fonc.2024.1382376 (2024).","journal-title":"Front. Oncol."},{"key":"1194_CR189","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1097\/JU.0000000000000272","volume":"202","author":"SJ Hectors","year":"2019","unstructured":"Hectors, S. J. et al. Radiomics features measured with multiparametric mMagnetic resonance imaging predict prostate cancer aggressiveness. J. Urol. 202, 498\u2013505 https:\/\/doi.org\/10.1097\/JU.0000000000000272 (2019).","journal-title":"J. Urol."},{"key":"1194_CR190","doi-asserted-by":"publisher","DOI":"10.1038\/s41746-019-0131-z","volume":"2","author":"N Hegde","year":"2019","unstructured":"Hegde, N. et al. Similar image search for histopathology: SMILY. NPJ Digit. Med. 2, 56 https:\/\/doi.org\/10.1038\/s41746-019-0131-z (2019).","journal-title":"NPJ Digit. Med."},{"key":"1194_CR191","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK-25-100051","volume":"45","author":"V Subbiah","year":"2025","unstructured":"Subbiah, V., Othus, M., Palma, J., Cuglievan, B. & Kurzrock, R. Designing clinical trials for patients with rare cancers: connecting the zebras. Am. Soc. Clin. Oncol. Educ. Book 45, e100051 https:\/\/doi.org\/10.1200\/EDBK-25-100051 (2025).","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"1194_CR192","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41591-022-02160-z","volume":"29","author":"V Subbiah","year":"2023","unstructured":"Subbiah, V. The next generation of evidence-based medicine. Nat. Med. 29, 49\u201358 https:\/\/doi.org\/10.1038\/s41591-022-02160-z (2023).","journal-title":"Nat. Med."},{"key":"1194_CR193","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1097\/JU.0000000000001290","volume":"204","author":"N Miura","year":"2020","unstructured":"Miura, N. et al. The prognostic impact of intraductal carcinoma of the prostate: a systematic review and meta-analysis. J. Urol. 204, 909\u2013917 https:\/\/doi.org\/10.1097\/JU.0000000000001290 (2020).","journal-title":"J. Urol."},{"key":"1194_CR194","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/pros.24100","volume":"81","author":"YG Tan","year":"2021","unstructured":"Tan, Y. G. et al. Prostatic ductal adenocarcinoma variant predicts worse pathological and oncological outcomes: insight from over 1000 consecutive patients from a large prospective uro-oncology registry. Prostate 81, 242\u2013251 https:\/\/doi.org\/10.1002\/pros.24100 (2021).","journal-title":"Prostate"},{"key":"1194_CR195","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05053152 (2026)."},{"key":"1194_CR196","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05652686 (2026)."},{"key":"1194_CR197","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04388852 (2026)."},{"key":"1194_CR198","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04429087 (2026)."},{"key":"1194_CR199","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT02861573 (2026)."},{"key":"1194_CR200","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04471727 (2026)."},{"key":"1194_CR201","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05760053 (2023)."},{"key":"1194_CR202","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05691465 (2026)."},{"key":"1194_CR203","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05413421 (2026)."},{"key":"1194_CR204","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT07111507 (2026)."},{"key":"1194_CR205","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06683846 (2025)."}],"container-title":["Nature Reviews Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41585-026-01194-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41585-026-01194-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41585-026-01194-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:02:10Z","timestamp":1792425730000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41585-026-01194-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,19]]},"references-count":205,"alternative-id":["1194"],"URL":"https:\/\/doi.org\/10.1038\/s41585-026-01194-z","relation":{},"ISSN":["1759-4812","1759-4820"],"issn-type":[{"value":"1759-4812","type":"print"},{"value":"1759-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,19]]},"assertion":[{"value":"22 September 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"B.V.L.A.M. has received compensation for consulting and\/or an advisory role from Astellas, AstraZeneca, Bayer, Johnson&Johnson\u00a0(J&J), Merck and Pfizer, for medical education activities from Astellas, AstraZeneca, Bayer, IPSEN, J&J and MSD, and has received travel support from Astellas, Bayer, Ferring, J&J, Herbarium. D.L.J. has received compensation for consulting and\/or an advisory role from Bristol Myers Squibb Co., J&J and Libbs Pharmaceutical, for medical education activities from Astellas, AstraZeneca, Bristol Myers Squibb Co., J&J, Libbs Pharmaceutical, Merck and Pfizer, and has received travel support from Boehringer Ingelheim and Merck. R.L. has received compensation for consulting from AstraZeneca, Bristol Myers Squibb Co., CG Oncology, enGene, J&J, Merck, Pfizer, Predicine, UroGen and Valar Labs. N.A. has received research funding to their institution from Arnivas, Astellas, AstraZeneca, Bavarian Nordic, Bayer, Bristol Myers Squibb, Calithera, Celldex, Clovis, Crispr, Eisai, Eli Lilly, EMD Serono, Exelixis, Genentech, Gilead, Glaxo Smith Kline, Immunomedics, Jn&J, Lava, Medivation, Merck, Nektar, Neoleukin, New Link Genetics, Novartis, Oric, Pfizer, Prometheus, Rexahn, Roche, Sanofi, Seattle Genetics, Takeda and Tracon. P.G. has received compensation for consulting from MSD, Bristol Myers Squibb, AstraZeneca, EMD Serono, Pfizer, Janssen, Roche, Astellas Pharma, Gilead Sciences, Strata Oncology AbbVie, Bicycle Therapeutics, Replimune, Daiichi Sankyo, Foundation Medicine, Eli Lilly, Urogen, Tyra Biosciences, Natera; and has received research funding from Bristol Myers Squibb, MSD, EMD Serono, Gilead Sciences, Acrivon Therapeutics, ALX Oncology, Genentech (paid to institution). P.E.S. is the current president of the Global Society of Rare GU Tumors. The remaining authors declare no conflicts of interest.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}